F16IL2

DRUG3 trials

Sponsors

Philogen S.p.A.

Conditions

Acute Myeloid Leukemia (AML) RelapseAcute Myeloid Leukemia, Relapsed, AdultNon-small Cell Lung Cancer (NSCLC)

Phase 1

A Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Very Low-dose Cytarabine in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation

TerminatedNCT02957032

Philogen S.p.A.Acute Myeloid Leukemia, Relapsed, Adult

Start: 2016-04-13End: 2023-09-29Target: 30Updated: 2023-10-10

Trial to Find and Investigate a Safe Dose of F16IL2 and BI 836858 in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation

CompletedNCT03207191

Philogen S.p.A.Acute Myeloid Leukemia (AML) Relapse

Start: 2016-12-02End: 2020-03-26Updated: 2022-04-20

F16IL2 in Combination With Nivolumab in Patients With Non-small Cell Lung Cancer

Philogen S.p.A.Non-small Cell Lung Cancer (NSCLC)

Start: 2017-03-09End: 2022-07-31Updated: 2022-07-21